Product Description
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ganzhou Hemay Pharmaceutical Co., Ltd
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Behcet Syndrome|Colitis, Ulcerative
Phase 2: Chronic Obstructive Pulmonary Disease|Dermatitis, Atopic
Phase 1: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07314242 |
HM005COPD2S01 | P2 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-12-31 |
12% |
2026-01-03 |
Primary Endpoints |
NCT05486104 |
HM005UC2S01 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2026-12-30 |
12% |
2026-04-04 |
Primary Endpoints |
NCT06145893 |
HM005BD3S01 | P3 |
Recruiting |
Behcet Syndrome |
2026-05-30 |
2025-04-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT05769946 |
HM005AD2S01 | P2 |
Completed |
Dermatitis, Atopic |
2024-01-24 |
2024-03-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06376474 |
HM005PS1S06 | P1 |
Recruiting |
Psoriasis |
2025-12-10 |
2025-03-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
CTR20243188 |
CTR20243188 | P1 |
Completed |
Psoriasis |
2024-10-11 |
2025-07-19 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06610903 |
HM005PS1S09 | P1 |
Completed |
Psoriasis |
2024-09-30 |
2025-03-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244741 |
CTR20244741 | P1 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20241161 |
CTR20241161 | P1 |
Recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20241162 |
CTR20241162 | P1 |
Active, not recruiting |
Psoriasis |
None |
2025-08-24 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20222690 |
CTR20222690 | P2 |
Recruiting |
Dermatitis, Atopic |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20221945 |
CTR20221945 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
None |
2026-04-05 |
Patient Enrollment|Treatments|Trial Status |
|
NCT07650942 |
HM005UC3S01 | P3 |
Not yet recruiting |
Colitis, Ulcerative |
2028-05-01 |
13% |
2026-06-17 |
Primary Endpoints |
CTR20232593 |
CTR20232593 | P3 |
Recruiting |
Behcet Syndrome |
None |
2025-04-29 |
||
NCT06908642 |
HM005CO1S01 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2025-06-03 |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06380153 |
HM005PS1S07 | P1 |
Completed |
Psoriasis |
2025-04-16 |
2025-12-05 |
Primary Completion Date|Primary Endpoints |
|
NCT06610890 |
HM005PS1S08 | P1 |
Completed |
Psoriasis |
2025-01-20 |
2025-12-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20243397 |
CTR20243397 | P1 |
Completed |
Psoriasis |
2025-01-20 |
2025-08-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|